General
Preferred name
rivastigmine
Synonyms
RIVASTIGMINE TARTRATE ()
SDZ-ENA 713 ()
ENA 713 ()
S-Rivastigmine ()
Exelon ()
Rivastigmine (tartrate) ()
SDZ-ENA 713, Exelon ()
Rivastigmine teva ()
Eluden ()
SDZ-212713 ()
Kerstipon ()
ONO-2540 ()
Somniton ()
Rivastigmine sandoz ()
Erastig ()
ENA-713D ()
Rivastigmine hexal ()
Alzest ()
Prometax ()
Voleze ()
Nimvastid ()
ENA-713 ()
SDZ-ENA-713 ()
SDZ-212-713 ()
Rivastigmine bitartrate ()
Rivastigmine hydrogen tartrate ()
Rivastigmine actavis ()
Rivastigmine hydrogentartrate ()
Rivastigmine-d6 (tartrate) ()
P&D ID
PD009603
CAS
129101-54-8
123441-03-2
194930-00-2
Tags
covalent binder
natural product
drug
available
Approved by
EMA
FDA
First approval
2000
1998
Drug Status
investigational
approved
withdrawn
Drug indication
Alzheimer disease
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Marketed formulations may contain rivastigmine hydrogen tartrate (PubChem CID 14254240). (GtoPdb)
DESCRIPTION Ceramidase inhibitor; antiproliferative (Tocris Bioactive Compound Library)
DESCRIPTION Dual AChE and BChE inhibitor (Tocriscreen Plus)
DESCRIPTION Rivastigmine Tartrate is a cholinesterase inhibitor with IC50 of 5.5 μM, and used as a parasympathomimetic or cholinergic agent for the treatment of mild to moderate Alzheimer disease. (BOC Sciences Bioactive Compounds)
Compound Sets
34
AdooQ Bioactive Compound Library
A11719
Axon Medchem Screening Library
3167
BOC Sciences Bioactive Compounds
rivastigmine-tartrate-cas-129101-54-8-item-84-56816
Cayman Chemical Bioactives
14270
25633
ChEMBL Approved Drugs
CHEMBL636
CHEMBL215645
ChEMBL Drugs
CHEMBL636
CHEMBL215645
Concise Guide to Pharmacology 2017/18
6602
Concise Guide to Pharmacology 2019/20
6602
Concise Guide to Pharmacology 2021/22
6602
Concise Guide to Pharmacology 2023/24
6602
CovalentInDB
CI000060
Drug Repurposing Hub
DrugBank
DB00989
DrugBank Approved Drugs
DB00989
DrugCentral
2392
DrugCentral Approved Drugs
2392
DrugMAP
DMG629M
DrugMAP Approved Drugs
DMG629M
EU-OPENSCREEN Bioactive Compound Library
EOS100371
Guide to Pharmacology
6602
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL636
MedChem Express Bioactive Compound Library
HY-11017
HY-17368
NCATS Inxight Approved Drugs
PKI06M3IW0
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
rivastigmine-tartrate-exelon
rivastigmine
TargetMol Bioactive Compound Library
T1628
T0229
The Spectrum Collection
Tocris Bioactive Compound Library
4440
Tocriscreen Plus
4440
Withdrawn 2.0
EMA36
External IDs
72
Properties
(calculated by RDKit )
Molecular Weight
250.17
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
1
Aromatic Ring Count
1
cLogP
2.76
TPSA
32.78
Fraction CSP3
0.5
Chiral centers
1.0
Largest ring
6.0
QED
0.82
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Pathway
Neuroscience
Neuronal Signaling
Target
AChR
AChE
ACHE, BCHE
AChE inhibitor
Cholinesterase (ChE)
Primary Target
Cholinesterases
MOA
AChR inhibitor
Inhibitor
Acetylcholinesterase Inhibitors
Butyrylcholinesterase Inhibitors
Acetylcholinesterase inhibitor
Member status
virtual
Indication
Alzheimer's disease, Parkinson's Disease, senile dementia
ATC
N06DA03
Source data